Indications
Treatment of moderate to severe chronic pain associated with osteoarthritis (OA) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or any opioid is ineffective, not tolerated or inappropriate.
Composition
- Active substance
- tanezumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Raylumis
- Active substance
- tanezumab
- ATC code
- N02
- Group
- Nervous system
- Therapeutic area
- Osteoarthritis, Pain
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Status
- Refused
- Refused